May 18, 2026

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

Conexiant

May 18, 2026

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.

Conexiant

May 15, 2026

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

KFF Health News

May 13, 2026

RFK Jr. Takes Health Agenda on the Road

Touring Ohio, RFK Jr. highlights food quality and recovery services while steering attention away from vaccine controversies.

KFF Health News

May 12, 2026

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

Conexiant

May 12, 2026

FDA Clears AI Sepsis Warning System

An FDA-cleared AI tool developed at Johns Hopkins detects sepsis up to 48 hours earlier than clinicians — and has cut related deaths by 18%.

Conexiant

May 11, 2026

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.

Conexiant

May 05, 2026

Prescribing Outside the Exam Room

A DEA case exposes how controlled substances can move outside clinical oversight.

Conexiant

May 04, 2026

FDA Expands ASCENIV Pediatric Use

Label change follows completion of required pediatric evaluation and updates prior age restrictions for treatment eligibility.

Conexiant

May 04, 2026

Food Fight Brewing in Hospitals

New federal diet push collides with clinical realities, as doctors weigh patient needs against policy signals.

KFF Health News